Ischemia-Reperfusion InjuryRIPCNCT07487220
Non-invasive Remote Ischemic PreConditioning (RIPC) in Free Flaps for Breast Reconstruction
A study testing Remote ischemic preconditiong in people with Ischemia-Reperfusion Injury and Free Flap, run by Ruhr University of Bochum at 1 site in Germany.
Trial summary
This prospective randomized clinical study investigates the effects of Remote Ischemic Conditioning (RIC) on tissue perfusion and ischemia-reperfusion injury in patients undergoing free flap reconstruction in reconstructive microsurgery. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Ischemia-Reperfusion Injury, Free Flap, Conditioning Therapy
- What is being tested?
- Remote ischemic preconditiong
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 49 participants
- Where
- 1 siteGermany
- Study dates
- 1 Apr 2021to 31 Dec 2023
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age ≥ 18 years
- Patients undergoing free flap reconstruction surgery for reconstruction of body surface defects
- Treatment at the Department of Plastic Surgery, BG Universitätsklinikum Bergmannsheil Bochum
- Ability to understand the study procedures
- Written informed consent to participate in the study
Who cannot join
- Refusal or inability to provide informed consent
- Contraindications to regional nerve block or perioperative procedures required for the study
- Any condition that prevents participation according to investigator judgment
Trial locations and contacts
1 site in 1 country.
Germany1 site
BG University Clinic Bergmannsheil
Bochum, North Rhine-Westphalia, 44789
About this study
Official title: Non-invasive Remote Ischemic PreConditioning in Free Flaps for Breast Reconstruction
This prospective randomized clinical study investigates the effects of Remote Ischemic Conditioning (RIC) on tissue perfusion and ischemia-reperfusion injury in patients undergoing free flap reconstruction in reconstructive microsurgery. RIC is a non-invasive conditioning technique using cyclic ischemia and reperfusion applied to an extremity, which may enhance microcirculation and induce tissue protection.
The study aims to evaluate whether preoperative RIC improves postoperative flap perfusion, reduces ischemia-reperfusion- related tissue damage, and enhances clinical outcomes such as flap survival, wound healing, and need for revision surgery. Patients undergoing free flap procedures will be randomized to receive either preoperative RIC (immediate or delayed) or no conditioning.
Additional analyses include continuous postoperative monitoring of microcirculation, histological and molecular assessment of tissue samples, and evaluation of circulating biomarkers associated with tissue protection.
Read the detailed description
Background Free flap reconstruction represents the gold standard for complex soft tissue defects arising from tumor resection, trauma, or chronic wounds. Despite refinements in microsurgical technique and perioperative management, flap-related complications, including partial necrosis, wound healing disorders, and total flap loss, continue to occur at clinically meaningful rates. The underlying pathophysiology involves obligatory ischemia during flap harvest and transfer, followed by reperfusion upon anastomosis completion. This ischemia-reperfusion (I/R) sequence triggers a cascade of oxidative stress, endothelial dysfunction, inflammatory activation, and microcirculatory failure that can ultimately compromise tissue viability.
Current intraoperative strategies to mitigate I/R injury remain limited, and no pharmacological or mechanical intervention has been established as standard of care in this context.
Scientific Rationale for Remote Ischemic Conditioning Remote Ischemic Conditioning (RIC) exploits the endogenous capacity of biological tissue to develop tolerance to ischemic stress when exposed to brief, non-lethal cycles of ischemia and reperfusion at a site distant from the target organ. Originally described in cardiac surgery, RIC has since been investigated across a range of ischemia-sensitive tissues and clinical scenarios. Proposed mechanisms include neuronal and humoral signaling pathways that activate cytoprotective programs, such as upregulation of heat shock proteins, modulation of the RISK (Reperfusion Injury Salvage Kinase) pathway, suppression of mitochondrial permeability transition pore opening, and attenuation of neutrophil-mediated endothelial injury.
Preclinical models of pedicled and free flaps have demonstrated improved perfusion, reduced apoptosis, and enhanced flap survival following RIC. However, these findings have not yet been translated into a prospective randomized clinical trial in reconstructive microsurgery.
Timing of Conditioning: Study Design Rationale A key unresolved question concerns the optimal timing of RIC relative to surgery. Two biologically distinct windows of protection have been described: an immediate window (within approximately 1-2 hours of the conditioning stimulus, mediated largely by post-translational protein modifications) and a delayed window (emerging 12*24 hours later, dependent on de novo protein synthesis and gene expression changes). To address this, the trial incorporates three parallel arms: a non-conditioned control group, an immediately preconditioned group (approximately 1 hour before surgery), and a delayed preconditioned group (12-24 hours preoperatively). This design enables direct comparison of both conditioning windows against each other and against standard care.
In cases where intraoperative findings necessitate unplanned revision surgery, a secondary randomization procedure is pre-specified to evaluate the potential benefit of RIC in the setting of threatened flap perfusion.
Intervention Protocol RIC is applied non-invasively to the upper arm using a standard pneumatic tourniquet. Each conditioning session consists of three alternating cycles of 10-minute ischemia (cuff inflated to approximately 250 mmHg, sufficient to occlude arterial inflow) and 10-minute reperfusion (cuff deflated), for a total session duration of 60 minutes. This protocol is consistent with those used in cardiovascular RIC trials and has a well-characterized safety profile.
Microcirculatory Monitoring Postoperative flap perfusion will be continuously assessed using a multimodal approach combining laser Doppler flowmetry and tissue spectrometry (O2C device or equivalent). These complementary techniques enable real-time, non-invasive quantification of microvascular flow, tissue oxygen saturation, and relative hemoglobin concentration. Measurements will be obtained at standardized time points throughout the first five postoperative days, allowing construction of perfusion trajectories and identification of early signs of compromised microcirculation.
Tissue and Biomarker Analyses Standardized biopsies will be obtained from clinically non-essential portions of the flap at defined intraoperative and early postoperative time points. Samples will undergo histological and immunohistochemical evaluation for markers of ischemic injury, cellular stress responses, inflammatory infiltration, and apoptosis. Parallel molecular analyses will characterize expression of proteins and signaling mediators implicated in I/R injury and cytoprotection.
Serial blood samples will be collected perioperatively to quantify circulating biomarkers, including but not limited to markers of oxidative damage, endothelial activation, and systemic inflammatory response. These analyses serve both to detect systemic correlates of local tissue protection and to identify candidate biomarkers for future use in monitoring RIC efficacy.
Clinical Outcome Assessment In addition to mechanistic endpoints, the trial will capture a comprehensive set of clinical outcomes through postoperative day 5 and beyond, including flap survival rate, incidence and severity of wound healing disorders, requirement for revision surgery or re-anastomosis, and total length of inpatient stay. Adverse events and protocol deviations will be systematically recorded.
Statistical Considerations Sample size estimation is based on the primary perfusion endpoint. Randomization will be performed centrally with stratification for relevant clinical variables. All primary analyses will follow the intention-to-treat principle; per-protocol analyses will be conducted as sensitivity analyses.
Significance If RIC is demonstrated to improve perfusion and reduce I/R injury in this setting, it would offer a compelling adjunct to reconstructive microsurgery: it is non-invasive, requires no specialized pharmacology, adds minimal procedural complexity, and is associated with a favorable safety profile in other surgical disciplines. The results of this trial are expected to inform evidence-based guidelines for perioperative conditioning in free flap surgery and to lay the groundwork for larger multicenter investigations.
- Conditions
- Ischemia-Reperfusion Injury, Free Flap, Conditioning Therapy
- Being tested
- Remote ischemic preconditiong
- Keywords
- ischemia, reperfusion, free flap, Wound Healing
- Medical subject headings
- Reperfusion Injury, Ischemia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Remote ischemic preconditiongDevice
The intervention consists of three cycles of ischemia and reperfusion applied to the upper arm using a pneumatic tourniquet. Each cycle includes 10 minutes of ischemia (inflation to approximately 250 mmHg) followed by 10 minutes of reperfusion (deflation). The total duration of the conditioning procedure is 60 minutes. Participants subsequently undergo free flap reconstruction according to standard institutional protocols.
| Study group | Role | What they receive |
|---|---|---|
| No RIPC | No intervention | No Remote Ischemic Conditioning (RIC) is administered. Participants receive standard perioperative care and undergo free flap reconstruction according to institutional protocols without any preconditioning intervention. |
| Early RIPC | Experimental | Remote Ischemic Conditioning (RIC) is performed 12-24 hours prior to surgery. The intervention consists of three cycles of ischemia and reperfusion applied to the upper arm using a pneumatic tourniquet. Each cycle includes 10 minutes of ischemia (inflation to approximately 250 mmHg) followed by 10 minutes of reperfusion (deflation). The total duration of the conditioning procedure is 60 minutes. Participants subsequently undergo free flap reconstruction according to standard institutional protocols. Receives: Device: Remote ischemic preconditiong |
| Late RIPC | Experimental | Remote Ischemic Conditioning (RIC) is performed one hour prior to surgery. The intervention consists of three cycles of ischemia and reperfusion applied to the upper arm using a pneumatic tourniquet. Each cycle includes 10 minutes of ischemia (inflation to approximately 250 mmHg) followed by 10 minutes of reperfusion (deflation). The total duration of the conditioning procedure is 60 minutes. Participants subsequently undergo free flap reconstruction according to standard institutional protocols. Receives: Device: Remote ischemic preconditiong |
What is being measured
The primary outcome is the main question the study is designed to answer.
Microcirculatory perfusion of free flap tissue measured by Laser-Doppler flowmetry and tissue spectrometry
Continuous assessment of microcirculatory perfusion parameters of free flap tissue using combined Laser-Doppler flowmetry and tissue spectrometry (O2C system). Parameters include blood flow (BF), tissue oxygen saturation (StO₂), and relative hemoglobin concentration (rHb) measured in the transplanted tissue to evaluate the effect of remote ischemic conditioning on flap perfusion and ischemia-reperfusion injury.
Measured: From intraoperative revascularization until postoperative day 5
Secondary outcomes (2)
Incidence of flap tissue necrosis following free flap reconstruction
Occurrence and extent of partial or complete flap necrosis following free tissue transfer surgery, assessed clinically during the postoperative observation period.
Measured: Up to postoperative day 5
Histological markers of vascularization and ischemia-reperfusion injury in flap tissue
Histological and immunohistochemical analysis of tissue biopsies obtained from the transplanted flap to assess vascularization, cellular damage, inflammatory response, and expression of ischemia-reperfusion related proteins (e.g., HIF1α, VEGF, TNFα, IL-1β). Analyses are performed on intraoperative and postoperative tissue samples to evaluate the biological effects of remote ischemic conditioning.
Measured: From intraoperative sampling after revascularization until postoperative day 5-7
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Mar 2026
- Study start1 Apr 2021
- Primary completion31 Dec 2022
- Study completion31 Dec 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Ischemia-Reperfusion InjuryStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Participants undergoing free flap reconstruction will be randomly assigned to one of three parallel groups: (1) no remote ischemic conditioning (control), (2) remote ischemic conditioning 12-24 hours prior to surgery, or (3) remote ischemic conditioning immediately prior to surgery. Participants remain in their assigned study arm throughout the study period. In cases of postoperative flap perfusion compromise requiring revision surgery, participants will undergo a secondary randomization to receive either additional remote ischemic conditioning or no conditioning prior to revision.
- Masking
- None (open label)
- Enrolment
- 49 participants (actual)
Sponsor and investigators
- Lead sponsor
- Ruhr University of Bochum
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, ALEXANDER FIEDLER, Ruhr University of Bochum
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07487220
- Sponsor's protocol ID
- 19-6752
- Acronym
- RIPC
- Status last verified
- Mar 2021
- First submitted
- 17 Mar 2026
- Last updated
- 25 Mar 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Individual participant data collected in this study will not be made publicly available. All study data will be pseudonymized and stored on secure institutional servers with access restricted to authorized study personnel. Data are collected as part of a single-center clinical study and contain potentially identifiable clinical information. Aggregated results may be published in scientific journals, but individual-level data will not be shared outside the study team in order to protect participant confidentiality.
Publications
Drysch M, Fiedler A, Schmidt SV, Reinkemeier F, Puscz F, Kurbacher T, Frey UH, Ochsenfarth C, Lehnhardt M, Wallner C, Sogorski A. Systemic downregulation of EV-associated MiRNAs following remote ischemic preconditioning. Sci Rep. 2025 Dec 11;15(1):43657. doi: 10.1038/s41598-025-31356-9.
PubMed 41381697Drysch M, Fiedler A, Kurbacher T, Schmidt SV, Reinkemeier F, Puscz F, Becerikli M, Fueth M, Weskamp P, Lehnhardt M, Wallner C, Sogorski A. Ischemia-Reperfusion Injury in Free Flaps: Molecular Mechanisms and Protective Effects of Remote Ischemic Preconditioning. J Cell Mol Med. 2025 Aug;29(15):e70739. doi: 10.1111/jcmm.70739.
PubMed 40771071
Study at a glance
From the registry record, last updated by the sponsor on 25 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Non-invasive Remote Ischemic PreConditioning in Free Flaps for Breast Reconstruction
- ClinicalTrials.gov ID
- NCT07487220
- Acronym / sponsor ID
- RIPC / 19-6752
- Conditions
- Ischemia-Reperfusion Injury, Free Flap, Conditioning Therapy
- Keywords
- ischemia, reperfusion, free flap, Wound Healing
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 49 participants (actual)
- Lead sponsor
- Ruhr University of BochumUniversity, hospital or other
- Study start
- 1 Apr 2021 (actual)
- Primary completion
- 31 Dec 2022 (actual)
- Study completion
- 31 Dec 2023 (actual)
- First posted
- 23 Mar 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This prospective randomized clinical study investigates the effects of Remote Ischemic Conditioning (RIC) on tissue perfusion and ischemia-reperfusion injury in patients undergoing free flap reconstruction in reconstructive microsurgery. RIC is a non-invasive conditioning technique using cyclic ischemia and reperfusion applied to an extremity, which may enhance microcirculation and induce tissue protection.
The study aims to evaluate whether preoperative RIC improves postoperative flap perfusion, reduces ischemia-reperfusion- related tissue damage, and enhances clinical outcomes such as flap survival, wound healing, and need for revision surgery. Patients undergoing free flap procedures will be randomized to receive either preoperative RIC (immediate or delayed) or no conditioning.
Additional analyses include continuous postoperative monitoring of microcirculation, histological and molecular assessment of tissue samples, and evaluation of circulating biomarkers associated with tissue protection.
Detailed description
Background Free flap reconstruction represents the gold standard for complex soft tissue defects arising from tumor resection, trauma, or chronic wounds. Despite refinements in microsurgical technique and perioperative management, flap-related complications, including partial necrosis, wound healing disorders, and total flap loss, continue to occur at clinically meaningful rates. The underlying pathophysiology involves obligatory ischemia during flap harvest and transfer, followed by reperfusion upon anastomosis completion. This ischemia-reperfusion (I/R) sequence triggers a cascade of oxidative stress, endothelial dysfunction, inflammatory activation, and microcirculatory failure that can ultimately compromise tissue viability.
Current intraoperative strategies to mitigate I/R injury remain limited, and no pharmacological or mechanical intervention has been established as standard of care in this context.
Scientific Rationale for Remote Ischemic Conditioning Remote Ischemic Conditioning (RIC) exploits the endogenous capacity of biological tissue to develop tolerance to ischemic stress when exposed to brief, non-lethal cycles of ischemia and reperfusion at a site distant from the target organ. Originally described in cardiac surgery, RIC has since been investigated across a range of ischemia-sensitive tissues and clinical scenarios. Proposed mechanisms include neuronal and humoral signaling pathways that activate cytoprotective programs, such as upregulation of heat shock proteins, modulation of the RISK (Reperfusion Injury Salvage Kinase) pathway, suppression of mitochondrial permeability transition pore opening, and attenuation of neutrophil-mediated endothelial injury.
Preclinical models of pedicled and free flaps have demonstrated improved perfusion, reduced apoptosis, and enhanced flap survival following RIC. However, these findings have not yet been translated into a prospective randomized clinical trial in reconstructive microsurgery.
Timing of Conditioning: Study Design Rationale A key unresolved question concerns the optimal timing of RIC relative to surgery. Two biologically distinct windows of protection have been described: an immediate window (within approximately 1-2 hours of the conditioning stimulus, mediated largely by post-translational protein modifications) and a delayed window (emerging 12*24 hours later, dependent on de novo protein synthesis and gene expression changes). To address this, the trial incorporates three parallel arms: a non-conditioned control group, an immediately preconditioned group (approximately 1 hour before surgery), and a delayed preconditioned group (12-24 hours preoperatively). This design enables direct comparison of both conditioning windows against each other and against standard care.
In cases where intraoperative findings necessitate unplanned revision surgery, a secondary randomization procedure is pre-specified to evaluate the potential benefit of RIC in the setting of threatened flap perfusion.
Intervention Protocol RIC is applied non-invasively to the upper arm using a standard pneumatic tourniquet. Each conditioning session consists of three alternating cycles of 10-minute ischemia (cuff inflated to approximately 250 mmHg, sufficient to occlude arterial inflow) and 10-minute reperfusion (cuff deflated), for a total session duration of 60 minutes. This protocol is consistent with those used in cardiovascular RIC trials and has a well-characterized safety profile.
Microcirculatory Monitoring Postoperative flap perfusion will be continuously assessed using a multimodal approach combining laser Doppler flowmetry and tissue spectrometry (O2C device or equivalent). These complementary techniques enable real-time, non-invasive quantification of microvascular flow, tissue oxygen saturation, and relative hemoglobin concentration. Measurements will be obtained at standardized time points throughout the first five postoperative days, allowing construction of perfusion trajectories and identification of early signs of compromised microcirculation.
Tissue and Biomarker Analyses Standardized biopsies will be obtained from clinically non-essential portions of the flap at defined intraoperative and early postoperative time points. Samples will undergo histological and immunohistochemical evaluation for markers of ischemic injury, cellular stress responses, inflammatory infiltration, and apoptosis. Parallel molecular analyses will characterize expression of proteins and signaling mediators implicated in I/R injury and cytoprotection.
Serial blood samples will be collected perioperatively to quantify circulating biomarkers, including but not limited to markers of oxidative damage, endothelial activation, and systemic inflammatory response. These analyses serve both to detect systemic correlates of local tissue protection and to identify candidate biomarkers for future use in monitoring RIC efficacy.
Clinical Outcome Assessment In addition to mechanistic endpoints, the trial will capture a comprehensive set of clinical outcomes through postoperative day 5 and beyond, including flap survival rate, incidence and severity of wound healing disorders, requirement for revision surgery or re-anastomosis, and total length of inpatient stay. Adverse events and protocol deviations will be systematically recorded.
Statistical Considerations Sample size estimation is based on the primary perfusion endpoint. Randomization will be performed centrally with stratification for relevant clinical variables. All primary analyses will follow the intention-to-treat principle; per-protocol analyses will be conducted as sensitivity analyses.
Significance If RIC is demonstrated to improve perfusion and reduce I/R injury in this setting, it would offer a compelling adjunct to reconstructive microsurgery: it is non-invasive, requires no specialized pharmacology, adds minimal procedural complexity, and is associated with a favorable safety profile in other surgical disciplines. The results of this trial are expected to inform evidence-based guidelines for perioperative conditioning in free flap surgery and to lay the groundwork for larger multicenter investigations.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 3
- Model description
- Participants undergoing free flap reconstruction will be randomly assigned to one of three parallel groups: (1) no remote ischemic conditioning (control), (2) remote ischemic conditioning 12-24 hours prior to surgery, or (3) remote ischemic conditioning immediately prior to surgery. Participants remain in their assigned study arm throughout the study period. In cases of postoperative flap perfusion compromise requiring revision surgery, participants will undergo a secondary randomization to receive either additional remote ischemic conditioning or no conditioning prior to revision.
| Arm | Type | Receives |
|---|---|---|
| No RIPC | No intervention | –No Remote Ischemic Conditioning (RIC) is administered. Participants receive standard perioperative care and undergo free flap reconstruction according to institutional protocols without any preconditioning intervention. |
| Early RIPC | Experimental | Device: Remote ischemic preconditiongRemote Ischemic Conditioning (RIC) is performed 12-24 hours prior to surgery. The intervention consists of three cycles of ischemia and reperfusion applied to the upper arm using a pneumatic tourniquet. Each cycle includes 10 minutes of ischemia (inflation to approximately 250 mmHg) followed by 10 minutes of reperfusion (deflation). The total duration of the conditioning procedure is 60 minutes. Participants subsequently undergo free flap reconstruction according to standard institutional protocols. |
| Late RIPC | Experimental | Device: Remote ischemic preconditiongRemote Ischemic Conditioning (RIC) is performed one hour prior to surgery. The intervention consists of three cycles of ischemia and reperfusion applied to the upper arm using a pneumatic tourniquet. Each cycle includes 10 minutes of ischemia (inflation to approximately 250 mmHg) followed by 10 minutes of reperfusion (deflation). The total duration of the conditioning procedure is 60 minutes. Participants subsequently undergo free flap reconstruction according to standard institutional protocols. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Age ≥ 18 years
- Patients undergoing free flap reconstruction surgery for reconstruction of body surface defects
- Treatment at the Department of Plastic Surgery, BG Universitätsklinikum Bergmannsheil Bochum
- Ability to understand the study procedures
- Written informed consent to participate in the study
Key exclusion criteria (3 listed)
- Refusal or inability to provide informed consent
- Contraindications to regional nerve block or perioperative procedures required for the study
- Any condition that prevents participation according to investigator judgment
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Remote ischemic preconditiongThe intervention consists of three cycles of ischemia and reperfusion applied to the upper arm using a pneumatic tourniquet. Each cycle includes 10 minutes of ischemia (inflation to approximately 250 mmHg) followed by 10 minutes of reperfusion (deflation). The total duration of the conditioning procedure is 60 minutes. Participants subsequently undergo free flap reconstruction according to standard institutional protocols. | Device | Early RIPC, Late RIPC |
Primary outcome
Microcirculatory perfusion of free flap tissue measured by Laser-Doppler flowmetry and tissue spectrometry
Time frame: From intraoperative revascularization until postoperative day 5
Continuous assessment of microcirculatory perfusion parameters of free flap tissue using combined Laser-Doppler flowmetry and tissue spectrometry (O2C system). Parameters include blood flow (BF), tissue oxygen saturation (StO₂), and relative hemoglobin concentration (rHb) measured in the transplanted tissue to evaluate the effect of remote ischemic conditioning on flap perfusion and ischemia-reperfusion injury.
2 secondary outcomes
Incidence of flap tissue necrosis following free flap reconstruction
Time frame: Up to postoperative day 5
Histological markers of vascularization and ischemia-reperfusion injury in flap tissue
Time frame: From intraoperative sampling after revascularization until postoperative day 5-7
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Mar 2026.
- Results publication: PubMed 41381697Drysch M, Fiedler A, Schmidt SV, Reinkemeier F, Puscz F, Kurbacher T, Frey UH, Ochsenfarth C, Lehnhardt M, Wallner C, Sogorski A. Systemic downregulation of EV-associated MiRNAs following remote ischemic preconditioning. Sci Rep. 2025 Dec 11;15(1):43657. doi: 10.1038/s41598-025-31356-9.
- Results publication: PubMed 40771071Drysch M, Fiedler A, Kurbacher T, Schmidt SV, Reinkemeier F, Puscz F, Becerikli M, Fueth M, Weskamp P, Lehnhardt M, Wallner C, Sogorski A. Ischemia-Reperfusion Injury in Free Flaps: Molecular Mechanisms and Protective Effects of Remote Ischemic Preconditioning. J Cell Mol Med. 2025 Aug;29(15):e70739. doi: 10.1111/jcmm.70739.
- Individual participant dataSharing planned: No. Individual participant data collected in this study will not be made publicly available. All study data will be pseudonymized and stored on secure institutional servers with access restricted to authorized study personnel. Data are collected as part of a single-center clinical study and contain potentially identifiable clinical information. Aggregated results may be published in scientific journals, but individual-level data will not be shared outside the study team in order to protect participant confidentiality.
Related trials for Ischemia-Reperfusion Injury
Recruiting
Minimal Sedation Versus Standard Continuous Sedation After Out-of-Hospital Cardiac Arrest
Out-of-Hospital Cardiac Arrest, Hypoxic-Ischemic Brain Injury
RecruitingPhase 2
Perioperative Ursodeoxycholic Acid for Renal Protection in Adults Undergoing Partial Nephrectomy for Renal Tumors
Kidney Cancer
RecruitingPhase 2
Prevention of Reperfusion Injury Outcomes Through Effective Cardioprotection Targeting Myocardial Infarction
Myocardial Infarction, Reperfusion Injury
RecruitingObservational study
Spectroscopic Assessment of Myocardial Oxygenation Changes in Pediatric Heart Surgery
Myocardial Ischemia, Heart Defects, Congenital
Recruiting
Cerebral Oximetry in Management of Post Cardiac Arrest
Post-Cardiac Arrest Syndrome, Post Cardiac Arrest Brain Injury
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Remote ischemic preconditiong in people with Ischemia-Reperfusion Injury and Free Flap, run by Ruhr University of Bochum at 1 site in Germany.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 25 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Microcirculatory perfusion of free flap tissue measured by Laser-Doppler flowmetry and tissue spectrometry (time frame: From intraoperative revascularization until postoperative day 5). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07487220, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Mar 2026.